Pharma/Biotech General Discussion


6 days ago

I always thought BioSpace was more of a news site but I noticed they have an entire BioSpace jobs section and the ability to search for Biotech and lifesciences jobs all over their website. Have they turned into a job site for biotech?

Have any of the recruiters or companies that you work with used BioSpace to find candidates? Additionally, has anyone used their services to find a job in the biotech and lifesciences industry?

What is a Complete Response Letter (CRL)

2 weeks ago

I bet Amarin AMRN is going to get a complete response letter at their upcoming AdCom meeting.

Apex Life Sciences

2 weeks ago

Alternatively, if I am unable to find a position with Apex, what is it like working for Apex Life Sciences? I know companies like Apex hire lifesciences professionals as they know the industry really well.

New Study Shows Promise in Treating More Patients with World’s Smallest Pacemaker

3 days ago

​Medtronic plc (NYSE:MDT) today announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study showing that an investigational set of algorithms in the Micra Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart

What are the Best Biotech Stocks?

2 weeks ago

AGRX was up 225% the other day after a 14-1 positive AdCom vote. FDA approval coming up next with several $3 price targets. Current price 1.38.

Biologics License Application BLA

2 weeks ago

What is a Biologics License Application, or BLA? We have a number of visitors who search for this question so we thought we would help answer it.

According to Wikipedia, A biologics license application (BLA) is defined by the U.S. Food and Drug Administration (FDA) as follows:

The biologics license application is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR 601.2). The BLA is regulated under 21 CFR 600 – 680. A BLA is su…

New Analysis Shows Icosapent Ethyl (Vascepa) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors

3 days ago

​Amarin Corporation plc (NASDAQ: AMRN) announced today a summary of results from a patient-level, cost-effectiveness analysis of icosapent ethyl (Vascepa®).1 This comprehensive analysis evaluated the cost-effectiveness of icosapent ethyl in reducing cardiovascular (CV) risk among high-risk patients

Trump to Allow Americans to Get Drugs From Canada?

3 months ago

Trump is usually a clown but he ends up doing some rational things every so often.

The Trump administration is exploring ways to allow Americans to import cheaper prescription drugs from Canada, the Department of Health and Human Services said on Wednesday.

The move holds out the promise of lower-cost prescription drugs, but many details would still need to be worked out. The administration will look into new rules to allow states, pharmacies and other parties to bring in drugs from Canada as par…

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

3 days ago

​Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that they have signed a definitive merger agreement to create a combined biopharmaceutical company focused on the commercialization and development of therapeutics to serve patients in the dermatology space. The Boards of Directors of both Foamix and Menlo have unanimously approved the transaction.

Biosimilars being delayed cost US healthcare system $7.6B

5 months ago

A new whitepaper published by the Association for Accessible Medication's Biosimilars Council found that patent tactics preventing biosimilars from entering the market have cost the U.S. healthcare system $7.6 billion since 2015.

Although the FDA has approved 20 biosimilars, only seven are available for patient use in the U.S.

The paper claims, "This is a direct result of the patent schemes used by some brand-name pharmaceutical companies to maintain their lucrative product pricing monopolies be…